Artivion, Inc. (FRA:CYL)

Market Cap	1.63B +32.7%
Revenue (ttm)	360.22M +9.8%
Net Income	-7.77M
EPS	-0.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	51.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	33.30
Previous Close	34.30
Day's Range	33.30 - 33.30
52-Week Range	19.44 - 41.10
Beta	n/a
RSI	26.94
Earnings Date	Feb 12, 2026

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offe...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1984
• Employees: 1,600
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CYL

Financial Performance

In 2024, Artivion's revenue was $388.54 million, an increase of 9.75% compared to the previous year's $354.00 million. Losses were -$13.34 million, -56.37% less than in 2023.

Financial numbers in USD